Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Latest Advancements in Biotech Consultancy Services: What You Need to Know

Jul 03, 2025

The Evolving Landscape of Biotech Consultancy

Biotech consultancy services are undergoing a remarkable transformation, driven by technological advancements and an increasing demand for innovative solutions. From startups to established firms, the role of biotech consultants has become pivotal in navigating the complexities of the industry. By leveraging cutting-edge tools and strategies, these consultants are providing invaluable insights that help businesses thrive in a competitive market.

Integration of Artificial Intelligence and Machine Learning

One of the most significant advancements in biotech consultancy is the integration of Artificial Intelligence (AI) and Machine Learning (ML). These technologies are revolutionizing data analysis, enabling consultants to provide more accurate predictions and tailored solutions. AI-driven platforms can process vast amounts of data at unprecedented speeds, uncovering patterns and trends that were previously unattainable.

artificial intelligence biotech

With AI and ML, biotech consultants can offer enhanced decision-making support, optimize research and development pipelines, and streamline regulatory compliance processes. This not only accelerates innovation but also reduces costs, making it more accessible for biotech companies to achieve their strategic objectives.

Advancements in Personalized Medicine

The rise of personalized medicine is another area where biotech consultancy services are making significant strides. Consultants are now equipped with the expertise to guide companies in developing therapies tailored to individual patients. By utilizing genetic information and other biomarkers, they help create more effective treatment plans, ultimately improving patient outcomes.

This shift towards personalized medicine requires a deep understanding of genomics and bioinformatics, areas where biotech consultants excel. They assist in designing clinical trials that account for genetic variability, ensuring that new treatments are both safe and effective for diverse populations.

Sustainability and Ethical Considerations

In addition to technological advancements, there is a growing emphasis on sustainability and ethical considerations within the biotech industry. Biotech consultants are increasingly focused on helping companies adopt environmentally friendly practices and adhere to ethical guidelines. This includes reducing waste, minimizing carbon footprints, and ensuring that products are developed responsibly.

sustainability biotech

Consultants play a crucial role in guiding businesses through complex regulatory landscapes, ensuring compliance with global standards. By prioritizing sustainability and ethics, they help build trust with stakeholders and consumers, fostering long-term success.

The Role of Digital Platforms in Consultancy

The digital transformation of biotech consultancy services has been accelerated by the development of advanced platforms that facilitate collaboration and knowledge sharing. These platforms allow consultants to connect with clients and industry experts worldwide, offering real-time solutions and insights.

By utilizing digital tools, consultants can provide more flexible and scalable services, adapting to the unique needs of each client. This approach enhances efficiency and allows for more personalized interactions, ultimately leading to better outcomes for biotech companies.

digital collaboration

The latest advancements in biotech consultancy are reshaping the industry, offering new opportunities for growth and innovation. By embracing AI, personalized medicine, sustainability, and digital platforms, biotech consultants are well-equipped to lead the way into the future. As the field continues to evolve, staying informed about these developments will be crucial for anyone involved in the biotech sector.